Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

It's an interesting question about defensins inhibiting RdRp, but I would guess the answer is no (after a very brief literature search).

The best part about the GMU ASV 21 presentation I think was this:

Ongoing Studies

• Additional research with coronaviruses,
alphaviruses and bunyaviruses
• Expansion to other cell types and in vivo
models (SARS-CoV-2)
• Mechanisms of action insights—impact on
entry and post-entry stages

Future Studies

• Exploratory work on the anti-inflammatory
properties of the compound during infection
• Testing Brilacidin against new SARS-CoV-2
variants
• Delivery and dosing strategies

Ha, can almost bold the whole thing!

It will be good to see what they come up with with for MOA of brilacidin as it impacts entry and/or post-entry SARS2 infection. Who knows, maybe they will find mpro or RdRp inhibition in vitro.

Would have liked to have seen the animal in-vivo work before human clinical trial, but man, research takes time.

I am just amazed that GMU RBL is doing all this work to test and help develop brilacidin. I wonder if we are giving them / Narayanan lab more money to do so. Still seems like a bargain, even if we do have to pay for it. It's just that we are at their whim for timelines. It does benefit GMU lab too I would guess if they can get federal grant money for this basic research.

For delivery and dosing strategies, I wonder if they can help us put brilacidin into an inhaled format and test in animals?

Really also looking forward to MOA studies and how that might impact different strains (alpha, beta, gamma, and especially delta).